James P. Dean, MD, PhD
The University of Texas MD Anderson Cancer CenterAuthored Items
Jillian Settlemire, RN, Jocelyn E. Bushart, ANP-BC, Sandra Dai, PhD, MS, James P. Dean, MD, PhD, David Arthur, PhD, Paul Barr, MD, Steven Coutre, MD
October 25, 2019 | November 2019 Vol 10, No 11
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase (BTK), is approved in the US for the treatment of CLL/SLL and allows for treatment without chemotherapy.
Edythe M. Greenberg, PhD, RN, FNP-BC, Jillian Settlemire, RN, Sandra Dai, PhD, MS, James P. Dean, MD, PhD, Tony Lin, PharmD, Steven Coutre, MD, Jan Berger, MD, PhD
November 9, 2018 | November 2018 Vol 9, NO 11
Ibrutinib is a first-in-class, once-daily inhibitor of BTK approved in the United States for treatment of CLL/SLL. RESONATE-2 is a phase 3 study comparing first-line ibrutinib versus chlorambucil in patients with CLL/SLL. Primary results (median follow-up, 18.4 months) demonstrated ibrutinib reduced risk of progressive disease (PD) or death by 84% (Burger, 2015).
Last modified: December 19, 2018